CINECA IRIS Institutional Research Information System

VASILE, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.687
AS - Asia 1.445
EU - Europa 1.159
SA - Sud America 255
AF - Africa 145
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.695
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.616
SG - Singapore 523
IT - Italia 411
CN - Cina 340
HK - Hong Kong 223
BR - Brasile 202
SE - Svezia 180
VN - Vietnam 170
GB - Regno Unito 109
DE - Germania 106
CI - Costa d'Avorio 79
FR - Francia 73
BG - Bulgaria 64
AT - Austria 54
RU - Federazione Russa 40
CA - Canada 35
IN - India 33
JP - Giappone 30
FI - Finlandia 26
BD - Bangladesh 24
PL - Polonia 23
TR - Turchia 21
NL - Olanda 20
AR - Argentina 18
MX - Messico 18
SN - Senegal 18
NG - Nigeria 16
ES - Italia 14
IQ - Iraq 14
PK - Pakistan 13
UA - Ucraina 9
VE - Venezuela 8
EC - Ecuador 7
ID - Indonesia 7
KE - Kenya 6
MA - Marocco 6
MY - Malesia 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
CO - Colombia 5
CR - Costa Rica 5
LT - Lituania 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
KR - Corea 4
PE - Perù 4
TN - Tunisia 4
CL - Cile 3
EG - Egitto 3
IL - Israele 3
IR - Iran 3
PA - Panama 3
RO - Romania 3
BY - Bielorussia 2
BZ - Belize 2
DK - Danimarca 2
HN - Honduras 2
HU - Ungheria 2
JO - Giordania 2
PH - Filippine 2
SV - El Salvador 2
TH - Thailandia 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BE - Belgio 1
DO - Repubblica Dominicana 1
EU - Europa 1
FJ - Figi 1
GD - Grenada 1
GY - Guiana 1
IE - Irlanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 5.695
Salva come PNG Salva come JPEG
Città #
Ashburn 349
Singapore 259
Hong Kong 217
Chandler 187
Fairfield 183
Dallas 173
Santa Clara 171
San Jose 156
Woodbridge 149
Houston 122
Shanghai 88
Abidjan 79
Beijing 79
New York 79
Seattle 79
Ann Arbor 74
Sofia 63
Los Angeles 62
Wilmington 62
Cambridge 60
Milan 59
Boardman 57
Serra 56
London 55
Vienna 48
Munich 47
Ho Chi Minh City 43
Florence 40
Princeton 40
Lawrence 36
Lauterbourg 32
Hanoi 30
Pisa 27
Medford 26
Frankfurt am Main 23
Rome 23
Tokyo 21
Buffalo 19
Ottawa 19
Dakar 18
San Diego 17
Des Moines 16
Lagos 16
Warsaw 16
Redondo Beach 15
Istanbul 14
Ogden 14
Da Nang 12
Orem 12
São Paulo 12
Dong Ket 11
Fuzhou 11
Helsinki 11
Turku 11
Council Bluffs 10
Düsseldorf 10
Kent 10
Nuremberg 10
Paris 10
Dearborn 9
Lancaster 9
Phoenix 9
Toronto 9
Baghdad 8
Belo Horizonte 8
Boulder 8
Bremen 8
Denver 8
Mexico City 7
Nanjing 7
Vicopisano 7
Chennai 6
Kunming 6
Poplar 6
Quanzhou 6
Redwood City 6
Stockholm 6
Haiphong 5
Hyderabad 5
Jiaxing 5
Lucca 5
Nairobi 5
Portsmouth 5
Amsterdam 4
Bari 4
Bắc Ninh 4
Casablanca 4
Guangzhou 4
Itaquaquecetuba 4
Jakarta 4
Manaus 4
Manchester 4
Montreal 4
Naples 4
Norwalk 4
Piombino 4
Porto Alegre 4
Ribeirão Preto 4
Rio de Janeiro 4
San José 4
Totale 3.879
Salva come PNG Salva come JPEG
Nome #
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 203
Pancreatic resections for metastases: A twenty-year experience from a tertiary care center 201
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 199
Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care 189
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival? 189
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 187
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 187
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 185
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 177
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 173
Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine 171
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 169
Ampullary adenocarcinomas: The immunohistochemical score of CDX2, CK7 and CK 20 identify pathological subtypes and their prognosis 166
Lights and shadows of molecular pathology and immunotherapy in adjuvant setting of patients with pancreatic ductal adenocarcinoma: Tumor volume and microsatellite instability inversely affect early progression free survival 163
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service 160
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 156
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 156
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 150
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 147
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 141
MICROSATELLITE INSTABILITY AND TUMOR VOLUME INVERSELY AFFECT EARLY PROGRESSION FREE SURVIVAL IN ADJUVANT SETTING OF PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA: LIGHTS AND SHADOWS OF MOLECULAR PATHOLOGY AND IMMUNOTHERAPY 139
Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. Is it still appealing in clinical trials? A meta-analysis and review of the literature 139
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 136
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 135
Robotic Versus Open Pancreatoduodenectomy With Vein Resection and Reconstruction: A Propensity Score-Matched Analysis 132
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 132
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 130
IDENTIFICATION OF PATHOLOGICAL AMPULLARY ADENOCARCINOMAS SUBTYPES AND THEIR PROGNOSIS USING THE IMMUNOHISTOCHEMICAL SCORE OF CDX2, CK7 AND CK 20 118
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 115
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 110
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 109
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 107
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 106
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 99
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer 89
ROS1 rearrangements are uncommon in biliary tract cancers 87
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 84
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 81
Gastric cancer: Translating novels concepts into clinical practice 79
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 79
Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution 68
Stomach preservation in pancreatectomy with celiac axis resection: Prediction and technique via Mayo Clinic classification 49
Totale 5.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.190
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.190
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202165 0 0 0 0 0 0 0 0 0 0 19 46
2021/2022371 7 9 7 10 54 84 14 9 12 29 31 105
2022/2023770 69 134 65 36 89 73 4 56 160 7 64 13
2023/2024431 28 30 73 32 44 69 34 7 10 15 43 46
2024/20251.408 9 51 28 85 128 176 80 59 158 181 173 280
2025/20261.702 157 186 204 215 222 122 266 69 98 144 19 0
Totale 5.792